News | Stents Bioresorbable | July 19, 2016

Good Samaritan Hospital First on West Coast to Offer Absorb Bioresorbable Stent

Retired microbiology professor first California patient to receive fully dissolving, bioresorbable stent following recent FDA approval

Abbott Absorb bioresorbable stent, dissolving BVS, first West Coast implant, Good Samaritan Hospital Los Angeles

July 19, 2016 — Good Samaritan Hospital, Los Angeles, is the first hospital on the West Coast to offer patients with coronary artery disease (CAD) Abbott's Absorb dissolving heart stent. Absorb is a drug-eluting coronary stent that dissolves, completely and naturally, in the body over time.

The stent treats coronary artery disease in a similar fashion to a metallic stent, propping the diseased vessel open to restore blood flow, but then disappears after the artery is healed, leaving no metal behind to restrict natural vessel motion.

Steven Burstein, M.D., interventional cardiologist and medical director of the Cardiac Catherization Laboratory at Good Samaritan Hospital, was the first on the West Coast to implant the Absorb stent to patient Ernest Matson, 69, a retired microbiology professor at the University of Guam, on July 11th. 

According to the National Heart, Lung and Blood Institute, CAD is the most common type of heart disease. CAD is a condition in which the arteries that supply blood to the heart become narrowed or blocked by a buildup of plaque. Plaque is made up of fat, cholesterol, calcium and other deposits that accumulate on the inner wall of the artery. Over time, the plaque hardens and narrows the coronary arteries, limiting the flow of oxygen-rich blood to the heart muscle. Areas of plaque can also rupture, causing a blood clot to form on the surface of the plaque. When blood flow to the heart is reduced or blocked, angina (chest pain) or a heart attack can occur.

While stents are traditionally made of metal, the Absorb stent is made of a naturally dissolving material similar to dissolving sutures. Absorb disappears completely in about three years, after it has done its job of keeping a clogged artery open and promoting healing of the treated artery segment. By contrast, metal stents are permanent implants.

"With outcomes equivalent to those of the best drug-eluting metallic stents, the Absorb scaffolding will dissolve within 18 to 24 months leaving behind a normal and natural vessel," said Burstein.  "This will not preclude further stenting or bypass surgery and may in fact make these future procedures, if indicated, easier to perform."

For more information: www.abbottvascular.com

Related Content

Videos | Cath Lab | August 13, 2018
Jeffrey Schussler, M.D., FACC, FSCAI, FSCCT, FACP, interventional cardiologist at Baylor Scott White Heart and Vascul
Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
FFR software on the GE Centricity CVIS. A trial from the 2018 EuroPCR meeting showed FFR improves long-term outcomes.
News | Cath Lab | May 29, 2018
May 29, 2018 — Ongoing controversy exists regarding the role of percutaneous coronary intervention (PCI) for stable c
SCAI Updates Consensus on Length of Stay for Percutaneous Coronary Intervention
News | Cath Lab | May 15, 2018
Revised guidelines incorporating new data on discharge criteria for patients undergoing elective percutaneous coronary...
No Benefit Found Using Sodium Bicarbonate, Acetylcysteine to Prevent Kidney Injury, the result of the PRESERVE Trial to prevent acute kidney injury (AKI), presented at SCAI 2018.  #SCAI, #SCAI2018,
Feature | Cath Lab | May 15, 2018
May 15, 2018 – The large-scale, international randomized PRESERVE clinical trial found high-risk patients for renal c
Angiogram of a STEMI patient.
News | Cath Lab | May 15, 2018
May 15, 2018 — A contemporary, real-world analysis shows lower mortality rates when culprit-only intervention is used
Recent Acquisitions Eroding Prices in Billion Dollar European Interventional Cardiology cath lab Market.
Feature | Cath Lab | May 07, 2018 | Simon Trinh and Jeffrey Wong
The European interventional cardiology market is currently valued at nearly $1.4 billion.
Videos | Cath Lab | May 07, 2018
Imran Ahmad, M.D., medical director of interventional cardiology, explains some of the new technologies his labs have
360 Photos | Cath Lab | April 20, 2018
A 360 degree view of the newest cath lab at Northwestern Medicine Central DuPage Hospital in Winfield, Ill., located
SCAI Announces Global Lecture Series for 2018 Scientific Sessions
News | Cath Lab | April 18, 2018
Many of the world’s leading interventional cardiologists and cardiovascular professionals will convene in San Diego,...
Overlay Init